Introduction
Polycystic ovary syndrome(PCOS, T2DM, endocrine disease
IMPAIRED GLUCOSE TOLERANCE, ENDOCRINE DISEASE
Polycystic ovary syndrome(PCOS) is the most common endocrine disease in women of reproductive age, affecting 6–15% based on the subjects investigated and the diagnostic standards applied (Glucagon-like peptide-1 receptor analogs(GLP-1RAs) administrations on the incretin system are a new therapy for T2DM through improving insulin resistance(IR) and impaired glucose tolerance (Beinaglutide is a short-acting recombinant human GLP-1 (rhGLP-1) with about 100% homology to human GLP-1 (7–36). It is an approved treatment for T2DM according to the Chinese Guideline for the Prevention and Treatment of T2DM (2017 edition) (